While MCT1 inhibition with AZD3965 is demonstrated to increase glycolytic intermediate levels and enzyme activity, causing intracellular lactate accumulation [83], a recent study in human breast cancer cells contradicts this, indicating that AZD3965 does not influence glycolytic activity or intracellular lactate accumulation [40]. The gene discussed is SLC16A1; the disease is breast carcinoma.